Smith-Lemli-Opitz Syndrome (SLOS) is a rare genetic disorder characterized by impaired cholesterol synthesis. The ICD-10 code for SLOS is Q87.1. In the previous ICD-9 coding system, the corresponding code was 277.4. SLOS affects various body systems and can lead to developmental delays, intellectual disabilities, and physical abnormalities. Early diagnosis and management are crucial for individuals with SLOS to optimize their quality of life.
Smith-Lemli-Opitz Syndrome (SLOS) is a rare genetic disorder characterized by impaired cholesterol synthesis. It is caused by mutations in the DHCR7 gene, which leads to reduced levels of the enzyme 7-dehydrocholesterol reductase. This enzyme is crucial for the production of cholesterol, a vital component for various physiological processes.
In terms of coding, the International Classification of Diseases, 10th Revision (ICD-10) provides a specific code for Smith-Lemli-Opitz Syndrome. The ICD-10 code for SLOS is Q87.1. This code falls under the category of "Other congenital malformation syndromes predominantly associated with short stature." Q87.1 is further classified as a "Congenital malformation syndromes predominantly associated with short stature."
On the other hand, the International Classification of Diseases, 9th Revision (ICD-9) does not have a specific code for Smith-Lemli-Opitz Syndrome. As ICD-9 lacks the specificity required to accurately represent this disorder, it may have been classified under a broader category or grouped with similar conditions.
It is important to note that the transition from ICD-9 to ICD-10 occurred in October 2015, and healthcare providers now primarily use ICD-10 codes for diagnostic purposes. The ICD-10 code Q87.1 for Smith-Lemli-Opitz Syndrome allows healthcare professionals to accurately identify and document this genetic disorder in medical records, facilitating effective communication, research, and appropriate management of affected individuals.